Background
EGFR antibodies are efficient in the treatment of patients with RAS wild type metastatic colorectal cancer (mCRC). However, 25% of those patients resist to th...
Background
Colorectal cancer is a real public health problem, it ranks third among cancers in terms of frequency the world and second in terms of mortality. Several envi...
Background
Anlotinib, a novel multi-targeting tyrosine kinase inhibitor (TKI), has been investigated in a variety of malignant tumors and has shown efficacy in clinical ...
Background
There is a strong body of evidence supporting use of immune checkpoint inhibitors (ICI) in unresectable mismatch repair-deficient (MMRd) / microsatellite unst...
Background
The variability of gene expression signatures across tumor sites has been previously documented [Stewart et al. 2017]. However, how this information can be ex...
Background
Gastric cancer is associated with poor prognosis. Curative resection alone leads to a dismal outcome of gastric and GEJ adenocarcinoma. In the western gastric...
Background
Death association protein-3 (DAP3) is an important growth/death regulator of cells, has been found to have important clinical value in various cancer. DELE1 (...
Background
One common genetic factor affecting the colorectal cancer (CRC) development and the outcome is the mutational status of the RAS gene family. Somatic variants ...
Background
Detection of MRD has emerged as a tool for risk stratification in patients with early stage CRC with potential implication for adjuvant therapy. Recently, the...
Background
Pancreatic ductal adenocarcinoma (PDAC) represents the majority of diagnosed pancreatic cancers and its mortality rates are well above 90%. This bleak scenari...